Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Geoffrey Whitley

Nurse Practitioner, Family Charlestown, MA Nurse Practitioner

NPI 1083994404 CMS profile 10690010

C8 Shipway Pl, Charlestown, MA 02129

Open in the dashboard

General payments

$65,586

1,159 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Geoffrey Whitley of Charlestown, MA is reported in the CMS Open Payments database as having received $65,586 across 1,159 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,987 106
2024 General $20,049 260
2023 General $9,675 263
2022 General $20,352 296
2021 General $4,523 234

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Geoffrey Whitley
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Geoffrey Whitley were reported at $10,987. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Geoffrey Whitley Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,523 $124 $35–$379 $132
2022 $20,352 $141 $44–$430 $149
2023 $9,675 $154 $49–$476 $160
2024 $20,049 $165 $51–$504 $164
2025 $10,987 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axsome Therapeutics, Inc. $28,610 82 payments
  2. Janssen Pharmaceuticals, Inc $14,101 82 payments
  3. Alkermes, Inc. $4,101 64 payments
  4. ITI, Inc. $3,984 161 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $2,390 117 payments
  6. Sunovion Pharmaceuticals Inc. $2,262 108 payments
  7. Neurocrine Biosciences, Inc. $2,160 82 payments
  8. Corium, Inc. $1,900 120 payments
  9. Lundbeck LLC $1,651 118 payments
  10. Otsuka America Pharmaceutical, Inc. $1,485 89 payments
  11. Other $2,941 136 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $25,515 1,123 payments
  2. Consulting Fee $18,789 8 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,660 5 payments
  4. Honoraria $6,988 2 payments
  5. Travel and Lodging $3,429 11 payments
  6. Education $205 10 payments
Products named General payments · program years 2021–2025
  1. Auvelity $28,610 82 payments
  2. SPRAVATO $13,688 68 payments
  3. LYBALVI Cns $3,862 58 payments
  4. LYBALVI Cns $3,459 39 payments
  5. CAPLYTA $3,380 141 payments
  6. LYBALVI Cns $3,178 26 payments
  7. LYBALVI Cns $3,178 26 payments
  8. LATUDA $2,262 108 payments
  9. INGREZZA $2,160 82 payments
  10. Azstarys $1,900 120 payments
  11. Other $14,013 674 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

4,320

Median for Nurse Practitioner: 389

Drug cost

$1,068,811

Median for Nurse Practitioner: $21,885

Branded share of claims

31.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 19 $174,059
Caplyta Lumateperone Tosylate Brand 94 $157,910
Rexulti Brexpiprazole Brand 104 $156,316
Austedo Xr Deutetrabenazine Brand 14 $130,896
Austedo Deutetrabenazine Brand 14 $105,595
Auvelity Dextromethorphan Hbr/Bupropion Brand 66 $89,743
Trintellix Vortioxetine Hydrobromide Brand 110 $54,252
Lybalvi Olanzapine/Samidorphan Malate Brand 19 $32,580
Vyvanse Lisdexamfetamine Dimesylate Brand 70 $26,098
Aripiprazole Generic 162 $24,035

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$93,774

Medicare's payments for the services billed

Medicare patients

89

Average age 58

Services billed

968

68 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 53%
Arthritis 45%
Diabetes 19%
COPD 17%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Auvelity
$14,993 66 —
CAPLYTA
$979 94 —
Azstarys
$870 — —
INGREZZA
$852 19 —
Qelbree
$771 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

1,159 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record